Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

A new study suggests that one of them, ubrogepant (Ubrelvy), may help people stop a migraine attack from happening when it’s used before the pain begins. A migraine attack is a complex ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

According to the medical journal Neurology, researchers said those who took ubrogepant or Ubrelvy were more than 70 per cent likely to function normally within a couple of hours. The drug was also ...

Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura. Approval of Ubrelvy follows an FDA okay for Eli Lilly’s ...

Buying Aliada Therapeutics would hand AbbVie a clinical-stage Alzheimer’s medicine and a technology that may be useful for a ...

Equipped with a rodent version of a Cybertruck, these driving rats reveal that positive experiences may sculpt the brain just ...

The company's migraine drugs, Qulipta and Ubrelvy, also are enjoying strong market momentum. Investors also have a lot to like about AbbVie's dividend. The company belongs to the elite group of ...

The top line is likely to have been driven by the depression drug Vraylar and the recently approved migraine drugs — Ubrelvy and Qulipta. The Zacks Consensus Estimate and our model estimate for ...